Molecular pathology for classification of tumors and for efficacy prediction of targeted therapies is often a quickly increasing subject. From the INSEMA review – a prospectively randomized review comparing SLNE vs. no SLNE in clients with early invasive breast cancer (≤ 5 cm, cN0) and breast-conserving therapy – details https://prussiad197bls5.wikissl.com/user